The FDA on August 10, 2022, granted regular approval to TABRECTA® (Capmatinib) for adult patients with metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumors have a mutation leading to Mesenchymal-Epithelial Transition (MET) exon 14 skipping, as detected by an FDA-approved test. TABRECTA® is a product of Novartis Pharmaceuticals Corp.
Bottom Ad
Advertisement
Subscribe
